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Abstract   
Strategies for biotechnology must take account of opportunities for research, innovation and 
business growth.  At a regional level, public-private collaborations provide potential for such growth 
and the creation of centres of excellence.  By considering recent progress in areas such as genomics, 
healthcare diagnostics, synthetic biology, gene editing and bio-digital technologies, opportunities for 
smart, strategic and specialised investment are discussed. These opportunities often involve 
convergent or disruptive technologies, combining for example elements of pharma-science, 
molecular biology, bioinformatics and novel device development to enhance biotechnology and the 
life sciences.  Analytical applications use novel devices in mobile health, predictive diagnostics and 
stratified medicine.  Synthetic biology provides opportunities for new product development and 
increased efficiency for existing processes. Successful centres of excellence should promote public-
private business partnerships, clustering and global collaborations based on excellence, smart 
strategies and innovation if they are to remain sustainable in the longer term. 




The biotechnology sector operates on an increasingly global basis, with the 25 biggest drug and 
biotech companies coming from eight different countries (Morrison & Lhäteenmäki 2017; NASDAQ 
Biotech Index, 2017). The sector has however, undergone considerable consolidation, including the 
$130 Bn merger of Dow Chemical with Du Pont and Chem China’s bid of $43 Bn for Syngenta, 
leading to a smaller number of truly global players. Major revenue earners include Abvie’s Humira 
monoclonal  antibody for arthritis, psoriasis, and Crohn’s disease therapy ($15.9 Bn), Gilead’s 
Harvoni small molecule for hepatitis C antiviral therapy ($13.8 Bn) and Celgene’s Revlimid for 
multiple myeloma and mantle cell lymphoma ($6.9 Bn; 1, illustrated  in Fig. 1).  Approximately 26% 
of revenue sales are currently spent on research and development, in what is increasingly an 
expensive escalating biotechnological arms race, with upwards of 40% of venture capital centred on 
just two areas: Boston Bay and San Francisco (Morrison & Lhäteenmäki, 2017). 
Amongst European companies, one of the biggest recent changes has seen Bayer bid $66 Bn for 
Monsanto, to create a global entity dedicated to innovation in healthcare, including 
pharmaceuticals, consumer & animal health and agriculture.  Digital farming combining big data with 
the internet of things, is one example of how Bayer will meet the challenges posed by world 
population increasing to 10 Bn by 2050. Farmland per capita will decline by 17% and climate change 
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is forecast to reduce yields by a further 17%.  This means an effective 60% productivity increase will 
be necessary to meet the needs of 10 Bn global citizens (Gartland & Gartland 2016; Food & 
Agriculture Organisation, 2016). Sustainably producing more food with fewer inputs will require 
precision data on needs and opportunities for growers. Bayer hope to provide an improved quality 
of life by combining aspects of their current crop protection portfolio with seed, trait and climate 
change platforms from Monsanto (Bayer, 2017).  At a national level, EU28’s largest biotechnology 
products pipeline comes from the UK, where €34.66 Bn was generated from pharma, medtech and 
biotechnology products in 2015 (PWC, 2017). This activity provides 482,000 UK jobs, €9.81 Bn tax 
take and equates to a Gross Value Added of €118,500 per employee, being the highest in Europe.  
What then are the areas of biotechnology where opportunities exist for smart, specialized strategies 
to emerge and be successful in research and innovation, including economic and future employment 
prospects? 
2.Synthetic Biology 
Producing new gene components, epigenetic factors and novel genomes from chemically 
synthesized nucleic acids is an area which has been growing steadily in recent years.  The ‘bio-parts’ 
economy is forecast to reach $14 Bn by 2019 and $39 Bn by 2030 through activities which currently 
have little or no regulation or restrictions on use (Manheim, 2016). This extends from relatively 
simple genetic switches, to potentially synthesising an artificial human genome in ‘Ultrasafe’ cell 
lines, genetically crippled to prevent escape or unforeseen adverse consequences through projects 
such as ‘Human Genome Project Write’ (Boeke et al., 2016).  Areas where this approach could prove 
beneficial include virus resistance, improving cancer treatments, testing of novel therapeutics and 
genome stability studies.  A distant goal is to produce sets of pan-human reference alleles for the 
dissection of disease susceptibility and complex phenotypes through gigabase scale genome 
engineering. Much progress has been made using yeast as model systems, including the construction 
of five new yeast chromosomes in Sc 2.0 (Richardson et al., 2017). Combining this type of approach 
with the search for a minimal genome, the JC Venter Institutes and Synthetic Genomics Inc. have 
developed JCVI Syn 3.0 through four cycles of design, synthesis and testing to identify life-essential 
functions using the Mycoplasma mycoides Syn 1.0 genome as a starting point (Hutchison et al., 
2016).  Potential applications include new protein products, increasing the efficiency of existing 
processes and enhancing biofuel production.  The JCVI Syn 3.0 genome consists of a mere 473 genes, 
with 33 genes associated with preservation of information, although 149 genes have unassigned 
functions (see Table 1).  Much further work is needed to design and build a fully synthetic organism 
(Service, 2016). 
[Table 1] 
Questions also remain about ownership and restrictions on use of synthetic organisms and products 
developed using synthetic biology tools (Manheim, 2016). Opportunities exist for a limited number 
of large scale synthetic biology factories, or innovation foundries, such as the SynbiCITE foundry 
based at Imperial College, providing advanced facilities and expertise at a commercial scale and cost 
that would be uneconomic for individual universities and institutions. SynbiCITE, established in 2013 
with €31 Mn support from a consortium of EU, government, research councils and industrial 
partners has now grown to more than 146 synthetic biology companies (SynbiCITE, 2017). In total 
more than €340 Mn was invested to set up six research centres for synthetic biology across the UK. 
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The breadth of potential applications of synthetic biology, is illustrated in Table 2. This area is 
accessible to all, requiring only significant design experience and imagination.   
[Table 2] 
 
3.Innovative biomedical devices 
Identifying, designing and constructing novel devices for biomedical purposes have been areas of 
massive growth in the last decade.  The ever expanding capabilities of smartphones, allied to new 
LED technologies, wireless internet protocols and cloud data warehousing now allow remote 
acquisition of real time patient data, interpretation and analysis without the previous necessity of 
attending a doctor’s surgery. This has been recognized by several charitable foundations and 
companies, such as Qualcom, who offer the Qualcom Tricorder X-Prize.  Innovative devices using 
smartphones have benefitted greatly from ‘Health Kit’ and ‘Research Kit’ software from Apple, 
particularly for diabetes management using iPhone or Apple Watch, and a growing number of 
android powered platforms, allowing anyone to create health applications.  Qualcom, an innovation 
engine, stimulated development of the first consumer-focussed, mobile diagnostic devices, inspired 
by the medical tricorder of Star Trek fame through a $10 Mn prize fund. More than 300 entrants had 
to demonstrate a palm sized device that could capture five key health metrics, provide patient tests 
on ten core health conditions including chronic obstructive pulmonary disease, urinary tract 
infection and atrial fibrillation, together with at least three further elective health conditions, such as 
whooping cough, HIV and shingles (Qualcom, 2017).  2017 Tricorder X-Prize winners were ‘DxtER’ 
from the American company Final Frontier Medical Devices, receiving the $2.5Mn first prize and the 
Taiwan-based Dynamical Biomarkers Group’s ‘Deep Q’ tricorder prototypes, in partnership with HTC, 
receiving $1 Mn (Basil Leaf Technology, 2017; Dynamical Biomarkers Group, 2017; Fig 2). DxtER 
integrates emergency medical room data with real time patient data, using non-invasive sensors.  
Acquired data is used by DxtER’s diagnostic engine to make a rapid assessment (18). Other 
smartphone based devices can be used for multitudinous applications, including fluorescence 
microscopy, DNA sequencing, mutation analysis, eye scanning and the diagnosis of infectious 
diseases (Michaud, 2017; Kuhnemund et al., 2017, Feng et al., 2017) with up to 98% accuracy.  These 
devices benefit from low cost (<$500 at scale) and ultimate portability, to allow for remote use in 
the field (Fig 3). Data can also be uploaded to the Cloud using the smartphone.   
[Figure 2] 
[Figure 3] 
Not all health applications of remote sensing have met with regulatory approval, as the Proteus 
Digital Health/Otsuka ingestible smart pill, combining a wireless sensor and the antipsychotic Abilify, 
to treat schizophrenia and bipolar disorder was initially refused USFDA approval (Thadani, 2017). 
Other similar Proteus sensors use a stomach skin patch and have achieved approval.     
3D-printing (additive manufacturing) has also been used to develop devices for a range of health 
applications, including a system for using a $500 consumer 3D printer, with a custom printed 
magnetic particle processing attachment replacing the usual extruder head.  This AI 
Biosciences/Johns Hopkins device allows extraction and processing of 12 DNA/RNA samples in 13 
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minutes proving effective for detection of infectious agents, including chlamydia, dengue fever and 
for general PCR amplification (Chan et al., 2016). Bespoke surgical implants, often made out of 
unique plastic polymers, or metal alloys, are increasingly being used to repair and protect against 
head trauma, for example following road accidents (University Utrecht Medical Centre, 2014). The 
range of 3D printing applications seems almost endless, from bacterially imprinted clothing, with 
pores able to change size and shape in response to heat and moisture (Wang et al., 2017), to 
regenerative medicine applications using bioprinted tissues, such as reconstructed ears and heart 
valves (Ameri et al., 2017). The search for novel antimicrobials is also benefitting from 3D printing, 
with standardised bacterial or viral impregnated materials being used for standardised testing of 
candidate molecules.  This is an increasingly important area for future research, as the World Health 
Organisation has recently published a list of 12 bacterial families posing the greatest risk to public 
health, through multidrug resistance, carbapenem and G3 cephalosporin resistance (WHO, 2017). 
4.Sequencing costs continue to decline 
The continuing dramatic reduction in the cost of genomic sequencing and increases in speed allow a 
human genome to be sequenced for considerably less than $1000 in a single day (Hoeksma, 2017). 
Oxford Nanopore, through their innovative portable MinION device offer a low cost (sub-$1000) 
entry into the world of genomics, able to sequence 1-20 Gbp per cell, and usable in almost any field 
setting, being powered from a laptop.  This extends the applicability of the technology, based, on 
voltage changes as a DNA strand passes across a nanopore, greatly. It can be scaled up through 
devices such as PromethION, combining up to 48 flow cells, each with up to 3,000 nanopore 
channels, giving up to 50 Gb capacity per run and an ability to sequence a human genome in 2-4 
hours (Loose, 2017; Magi et al., 2017).  Other massive scale sequencing systems, such as Illumina’s 
multi-channel flow cells (Fig 4), for example, are combining their HiSeqX technology with Philips 
artificial intelligence platform in the identification of key mutations and the provision of data for 
clinicians.  Illumina, who are also working with IBM Watson Health, now believe that the $100 
genome is close to fruition. There is however, a clear and as yet unmet need for genomics to be 
mainstreamed at the point of care, alongside radiology and pathology services data (Hoeksma, 
2017). Perhaps the largest current genomics project is Genomics England – Illumina ’100,000 
Genomes Project’ partnership, aiming to meet this ambitious target by 2018, having reached 36,083 
genomes by Oct 1, 2017 (Genomics England, 2017).  Genomics England Clinical Interpretation 
Partnerships (GECIPS), open to international scientists and clinicians, will play an important role in 
analysing individual rare diseases or conditions from the findings.  
[Figure 4] 
Together with several bioinformatics and computing companies, big data and artificial intelligence 
techniques are being utilised to educate a new type of professional, able to translate and interpret 
such data for incorporation in clinical workflows.  Universities and bodies such as the Wellcome 
Trust/Sanger Institute in Cambridge have recognized this and are now offering big data 
interpretation apprenticeships to meet burgeoning demand (Sanger Inst/Wellcome Trust, 2017) with 
the creation of up to 56,000 new jobs forecast by 2030. Amongst other large scale genomics 
projects, Astra Zeneca aim to analyse 2 million genomes in the coming decade; GSK are working 
closely with the US sequencers Regeneron, and the UK BioBank to sequence 500,000 exomes from 
de-identified UK citizens over the age of 40 years, over the next 3-5 years (Withers, 2017; Hirschler, 
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2017).  Typically, such large scale projects involve commercial partners having closed access to public 
data for nine months, followed by freely available public access through for example, UK BioBank . A 
focus of such operations has emerged in the UK ‘Golden Triangle’, between London, Oxford and 
Cambridge, where a critical mass of facilities and specialist expertise is being constructed. Synergies 
provided by companies such as Oxford Nanopore, Horizon Discovery, Eagle Genomics and Congenica 
are well placed to take advantage of these developments, although as yet, there is not a large scale 
sequencing facility quality assured to international clinical standards (Hirschler, 2017). This means 
that Astra Zeneca, for example, continue to have to send diagnostic samples for processing to the 
United States.  This is an opportunity for a European ‘Mega-Hub’ to evolve, able to compete with 
American and Chinese facilities, creating thousands of jobs, as well as technological, economic and 
societal advantages. This has been recognized by the UK Chief Medical Officer (Dame Sally Davies) 
who has described a new genomics era ‘Gold Rush’ in her 2016 annual report ‘Generation Genome’ 
(Davies et al., 2017).  As the largest organised health system in the world, the role of the National 
Health Service (NHS) in finding new and innovative ways to bring genomics data and interpretations 
to point of treatment facilities across the UK, to realise these benefits cannot be underestimated 
(Davies et al., 2017).  Other countries, both within Europe and further afield, are developing similarly 
ambitious genomics and clinical bioinformatics targets, such as American plans to link up more than 
1 million genotypic, phenotypic and lifestyle data sets to speed up biomedical discovery, with a €441 
Mn budget (Obama, 2016). Precision medicine initiatives extend to ROADMAP, combining US 
National Institutes of Health EpiGenomics Consortium and ENCODE data to boost understanding of 
the role of individual genetic variants in disease susceptibility and prognoses (Herceg et al., 2017; 
Kuiper et al., 2015), as well as the EU Innovative Medicines Initiative, with a 10-year budget of €5.3 
Bn to identify and address bottlenecks in the development of novel drugs, therapies and biomedical 
devices, including rapid approvals. So far, 90 projects have involved 863 participants, delivering 6995 
project outputs and 2686 publications (Innovative Medicines Initiative, 2017). Bottlenecks in drug 
discovery have been addressed by making trials more reliable, improving translatability, and helping 
companies to predict patient safety earlier on in the development process, by encouraging 
collaboration in a pre-competitive space, sharing knowledge and skills, and data pooling. Recent 
examples include establishing a European biobank for quality assured human induced pluripotent 
stems cells (De Sousa et al., 2017), developing a portable rapid diagnostics device for filovirus nucleic 
acids testing (e.g. Ebola virus),  in 75 minutes (MOFINA Project, 2017), and discovering new ways to 
target drug-resistant bacteria (Chan et al., 2017).   By combining different cutting edge expertise and 
stakeholders, this EU-led public private partnership is successfully identifying new ways to tackle 
global health challenges.  
The combination of mobile (m-) health and big data tools is providing new insights into disease 
prevention, diagnostics and therapies, especially when allied to artificial intelligence, novel sensors, 
smartphones and decision making tools in a market estimated to exceed €26 Bn by 2020 (Albrecht, 
2016). The e-Estonia Portal is an early example of a European model for such systems, based on an 
efficient ‘once only’ principle of data acquisition, allowing multiple interrogation of cloud data using 
standardised formats and a capture-analyse-improve approach.  Other European states are adopting 
similar, common format systems, including several German lände (Liiv, 2017; Becker et al., 2014). 
Direct to consumer tests for DNA ancestry (23andMe, 2017), pharmacogenomic predictions of the 
suitability of particular drugs for individual patients to identify poor metabolisers (Somogyi and 
Phillips, 2017) and predictive genotypic analyses for as little as €100, can all contribute to the m-
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health revolution, but not without careful interpretation of results (Genes-for-Good, 2017). For 
example, two CYP2C19 alleles found in up to 14% of patients, are associated with poor clopidogrel 
(Plavix) metabolism, linked to a high risk of treatment failure for this globally significant medicine 
used to reduce heart attack and stroke risk (Topol & Schork, 2011). This also represents a substantial 
waste of resources, perhaps as much as $1.5 Bn annually. A further area of blossoming personalised 
activity is consumer demand for gut microbiome profiling.  ‘SmartGut’ (µBiome) testing assesses gut 
bacterial diversity from faecal samples, using 16s ribosomal RNA sequencing and comparison with a 
100,000 microbial gut sample database, at a cost of $89 for US health workers.  Interpretable data 
includes information on 26 microbial species with risk factors for disease or long term conditions 
(Costandi, 2013; Shankar, 2017).  ‘Map My Gut’ is a $381 assessment of faecal microbes, allowing 
comparison with 16s rRNA and metagenomics sequence databases and can be commissioned by 
NHS health professionals (Beaumont & Goodrich, 2016). As public understanding of personalised 
genomics rises, the links between microbial diversity and disease are enhanced, assessments such as 
these will become increasingly popular and less expensive.  
There are however many questions relating to personal genomics, ethics and privacy which have not 
yet been fully addressed.  For example, do direct-to-consumer kits sold as part of a €9.6 Bn market 
sector provide adequate privacy protection (Aitken et al., 2016)? A recent survey found that 28% of 
UK consumer genetic tests did not comply with UK Human Genetics Commission guidelines 
(Geoghegan, 2016; Hall et al., 2017).  Questions regarding informed consent, preservation of 
anonymity, data confidentiality, de-/re-identification, ownership of intellectual property arising from 
personal data and the ability to withdraw at any time are not yet fully answered (Krieger et al., 
2016). Whether informed consent also relates to future rather than merely present research is also 
frequently unclear. Without adequate consideration, these questions could adversely impact on risk 
perception, medical decision making, current and future participation in personal genomic testing. 
American survey data suggests that direct to consumer test users learn from their individual results 
and modify their beliefs, particularly when seeking further medical actions relating to large or 
unexpected risks (Aitken et al., 2016; Hall et al., 2017). Whether this applies equally in other 
marketplaces remains unclear.  There is however, a clear need for greater public education around 
the issues related to personal genomic testing, so that medical decision making, can be better 
informed, especially by and for the benefit of patients (Krieger et al., 2016). One area where big 
data, artificial intelligence and transcriptomics, the study of the complete set of RNA sequences 
produced by the genome under particular conditions, are likely to bring substantial benefits is in 
modelling the cancer transcriptome. Using the Swedish national supercomputer, University of 
Stockholm scientists mapped the transcriptomics of 315 genes to 17 major cancer types using RNA, 
protein and outcome data from 8,000 individual patients and clinical metadata, to produce 900,000 
patient survival profiles for personalised patient models (Uhlen et al., 2017).  Findings from this, the 
biggest study of its kind to date, suggest that within tumour variation can be as large as that 
between tumour types, reflecting the heterogeneity of cancers.  An overall tendency for shorter 
survival to be associated with up-regulation (increased transcription) of genes associated with 
mitosis and cell growth was observed, together with down–regulation of cell differentiation 
associated genes. That there is a need for actions and not just words on issues of patient data and 
public health has been highlighted (Parry, 2017), alongside recognition of the need to consider 
implications for other family members, both current and future, in making decisions on what to do 
with personal genomics data.  Inter-generational differences in how insurance companies and 
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pension funds might choose to interpret such data must also be taken into account (Economist, 
2017).  
 
5.CRISPR Genome editing systems take command 
Clustered regularly interspersed short palindromic repeats (CRISPR) have in recent years become a 
ubiquitous system for altering the genome of almost any organism (Zetsche et al., 2015).  In the first 
nine months of 2017, 2,568 publications citing CRISPR were found in PUBMED  and the cumulative 
total of publications or patent applications citing CRISPR exceeded 64,500 since 2002 (Makarova, 
2011).  The diversity of CRISPR systems and the associated CRISPR effector proteins, such as Cas9, 
provide bacterial adaptive immunity, having a defensive role not unlike restriction endonucleases. 
Crucial to their effectiveness is an ability to recognise double stranded DNA, or sometimes RNA, and 
produce precise cuts in a predictable, structured fashion (Makarova, 2011; Makarova et al., 2015, Fig 
5).  A guide RNA can be programmed to match any specific sequence, to which Cas9 is attached.  The 
guide RNA binds to target DNA, following the rules of base pairing, allowing Cas9 to align precisely 
and cut both DNA strands.  The cut DNA can be altered with extra DNA sequences inserted, or the 
target DNA sequence eliminated by deletion (Barrangou & Doudna, 2016; Charpentier, 2015, Fig 5).  
The range of CRISPR-Cas systems are classified by the nature and configuration of their Cas proteins.  
Although other gene editing systems exist, such as Zinc finger nucleases and TALENS (Ruiz de 
Galaretta & Lujambio, 2017), these do not appear to have as much programmable flexibility as 
CRISPR systems.  Class 1 CRISPR systems use several Cas proteins and the CRISPR RNA (crRNA) in 
cleaving DNA, whilst Class 2 systems use a larger single Cas Protein together with crRNA (Makarova 
et al., 2015). Cpf1 for example, is a Class 2 CRISPR system based on a 1,300 amino acid protein from 
Prevotella and Francisella (Zetsche et al., 2017), with a single RNA guided endonuclease, which may 
have wider and simpler applicability in manipulating genomes (Zaidi et al., 2017).   Other Cpf1 
enzymes have been isolated from, amongst others, Acidaminococcus and Lachnospiraceae bacteria 
and shown to be effective in editing human genomes (Zetsche et al., 2015).  
[Figure 5]  
CRISPR systems have been used to reduce HIV-1 retroviral load and virus production 20-fold in 
cultured cells (Zhu et al., 2015), and to excise HIV-1 progenomes in human T-cells (Kaminski et al., 
2016), whilst also being useful in screening for protein domains in disease target genes (Shi et al., 
2015) and in the epigenetic mapping of p53 ‘Guardian Angel’ binding sites (Korkmaz et al., 2016). 
CRISPR-Cas is also being used as a DNA-based search tool for smart antimicrobials, for selective 
eradication of microbial pathogens without risking the development of antibiotic resistance 
(Barrangou & Ousterout, 2017) and has even been used to store static images and a digital movie of 
a galloping mare in the E. coli genome (Shipman et al., 2017). Food based applications of CRISPR 
technology to improve crop plants such as non-browning white mushroom (Agaricus bisporus, Fig 6) 
have been declared as not requiring regulation in the United States (Waltz, 2016), in a similar fashion 
to browning resistant Arctic Apples produced using RNAi and non-browning potatoes silencing up to 
four polyphenol oxidase genes (Waltz, 2015). The EU continues to avoid making a decision on 
whether products of CRISPR use would be categorised as genetically modified or not, even though 
they may reach the commercial marketplace before CRISPR-derived medical drugs (Bomgardner, 




Gene editing is not, as yet, globally regulated, with at least partially unanswered questions relating 
to off-target effects and mosaicism, where chimaeric products could be counter-productive (Broad 
Institute, 2017).  Issues surrounding consequential liability  and ultimate patent rights are also being 
contested, although the Broad Institute, together with Harvard University and MIT, who have been 
granted US patents on CRISPR, have adopted an enlightened approach to licensing for uses excluding 
human germline editing, tobacco and ‘terminator’ seed type applications, based on ‘inclusive 
innovation’ principles (Luo et al., 2016). Perhaps the best efforts to develop a set of guidelines for 
the application of genome editing technologies has come from the National Academies and 
Wellcome Trust, who concluded that significant scientific progress was needed before genome 
editing could satisfy risk/benefit standards for starting clinical trials for anything beyond treatment 
or prevention of disease or disability (National Academies Press/Wellcome Trust, 2017).  These 
authors, amongst many others, also distinguish between uses for somatic cells in humans and 
potential germline applications, which could affect future generations.    
Whilst earlier research-led studies in human embryo genomic editing using CRISPR proved 
successful, using abnormal and therefore waste embryos, low efficiency and mosaicism proved 
problematic, as expected from animal studies (Chen et al., 2015). By combining CRISPR-Cas9 
treatment with intra-cytoplasmic sperm injection (icsi) in metaphase II of meiosis, scientists from 
Oregon Health & Science University, Salk Institute and University of Korea were able to overcome 
some of these problems.  A team led by Shoukhrat Matalipov, has corrected the dominant 
pathogenic gene mutation MyBPC3 in viable human embryos (Ma et al., 2017).  This mutation, found 
in up to 8% of some Indian populations and affecting up to 1 in 500 adults, leads to hypertrophic 
cardiac myopathy. This is a significant cause of heart failure in young adults (Maron et al., 1995)). 
The combination of icsi and metaphase II editing (Lin et al., 2014) successfully corrected 72% of 
embryos to wild type genotypes with mosaicism limited to 25%, with no evidence of off-target 
effects when these embryos were allowed to reach the blastocyst stage, as assessed by whole 
exome and genomic sequencing (Fig 7). This approach which has significant efficiency, accuracy and 
safety advantages over other methods, has great potential as an adjunct to preimplantation genetic 
diagnosis in the correction of heritable mutations in human embryos.  Sun Yat-sen University 
scientists recently successfully swopped a single adenine-thymine base pair for a guanine-cytosine 
base pair using base editing (Kim et al., 2017), to correct a beta-thalassemia gene defect in human 
embryos (Liang et al., 2017). As with the Oregon study none of these edited embryos were allowed 
to develop beyond the blastocyst stage, meaning that none were implanted.  Despite massive global 
media hype, these studies are as yet a long way from clinical application, but do represent significant 
staging posts on the journey towards human germline editing in years to come.   Faster progress is 
likely around opportunities in understanding more fully how tools like CRISPR work (Stella et al., 
2017) and in agricultural gene editing leading to enhanced crops and animals. For example, CRISPR 
edited pigs produced using the uncoupling protein UCP1 gene from mice lowers fat content and 






6. Increasing scope for novel cancer therapies 
Two single-shot chimaeric antigen receptor T-cell (CAR-T) therapies have received US Food & Drug 
Administration approval, as novel cancer therapies move forward.  CAR-T therapies combine an 
antibody derived targeting fragment fused to signalling domains capable of activating T-cells (Gross 
& Eshhar, 2016). Although not without significant risks, Novartis’ CAR-T Kymriah and Kite Pharma’s 
(a recent $10 Bn purchase by Gilead) Yescarta offer hope for certain types of relapsed leukaemia and 
possibly other blood cancers. Yescarta clinical trials showed a 72% therapy response rate, with 51% 
of patients showing complete remission (Rodriguez Fernandez, 2017). Caution is needed when 
considering CAR-T therapies, however, as several deaths due to side effects probably related to 
cytokine storms have been observed, and a number of other CAR-T trials have been abandoned.  
Such single-shot infusions come at a very high price, with Gilead listing Yescarta therapy at €316,000 
and Novartis’ Kymriah priced at €398,000, for blood cancer patients already having had two other 
failed treatment lines.  The development of novel biotech cancer therapies is likely to continue to be 
an emotive, exciting and profitable vista for the future, especially if costs can be reduced as more 
alternatives approach regulatory approval (Sadelain, 2017). Such approaches would seem ideal 
candidates for Innovative Medicines Initiative or Breakthrough Drug support (Innovative Medicines 
Initiative, 2017). 
 
7. The power of partnerships and international collaboration 
Few biotechnological opportunities can be effectively exploited by single countries alone, as the 
complexity and cost of research and development continues to rise and applications increasingly 
require multidisciplinary inputs. This could be in m-health where health-apps have been recognised 
as a global opportunity for the insurance industry (Guest, 2017) or web-based data sharing platforms 
such as MyGene2 which allow families and clinicians seeking molecular diagnoses to share data 
(Karow, 2017). International and public-private partnerships will become increasingly important in 
realising potential such as in understanding the basis of so-called ‘rare’ diseases. These affect less 
than 1 in 2,000 people in the EU28. Collectively however, such rare diseases are actually quite 
common (Boycott et al., 2017).  International partnerships and shared data can improve the 
probability of finding other mutations in the same or similar genes. MyGene2 has accumulated 1,225 
freely available data sets in its first year from 880 clinicians, families and researchers on 723 genes 
including many unique disease gene variants (Karow, 2017).  The International Rare Diseases 
Research Consortium is developing strategies for enabling the diagnosis of all rare genetic diseases 
using common standards, tools and genomic analysis utilities (Parry, 2017; Boycott et al., 2017; 
Global Alliance for Genomics and Health, 2017; Im et al., 2015; Gabrielczyk, 2017). This should 
ultimately improve rapid diagnosis and treatment prospects for rare disease sufferers through 
collaborative partnerships.  Regions seeking opportunities in biotechnology should seek to input 
their unique expertise and where possible facilities and investment to international and public-
private partnerships such as these to create the new knowledge, jobs, economic and societal 
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Table 1 JCVI Syn 3.0 Gene Functions 
Function Genes 
Gene Expression 41% 
Cell Membranes 18% 
Cytosolic Metabolism 17% 
Genome Preservation 7% 
Unknown Function 17% 
 





Table 2 Application Areas for Synthetic Biology 
Application Example Refs 
Gene Circuits Assembly Strand displacement switches in 




Synthetic Theranostics Stem cell manipulations  Rathman et al. 
2017 
Alginate Bead Delivery Systems Protection against liver failure in 
mice  
Service, 2016 
Novel Flavours, Food and Drinks ‘Raspberry’ ketones from wine 
yeasts  
Jagtap et al., 
2017 
Identity Preservation Reversible data hiding using DNA 
computing  
Wang et al., 
2017 
Precision Oncology Tailored tumour diagnosis and 

















































Figure 7 Human blastocyst 
Source: Open i- Open Access Pub Med Central 
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